Mehnert, Janice M.
https://orcid.org/0000-0001-9492-9264
Mayo Clinic
Rutgers, The State University of New Jersey
Citations 2
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial
Chesney, Jason , Collichio, Frances A. , Hamid, Omid , Ross, Merrick I. , Friedlander, Philip , Yi, Min , Snyder, Wendy, Mehnert, Janice M. , Puzanov, Igor , Singh, Parminder Pal , Milhem, Mohammed , Glaspy, John A. , Garbe, Claus , Logan, Theodore F. , Hauschild, Axel , Lebbé, Célèste
Regular and young investigator award abstracts | November 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: A263.2-A264
Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.
Gangadhar, Tara C., Hamid, Omid , Dummer, Reinhard , Mehnert, Janice M. , Celentano, Kellie Ann, Lindia, Jill A., Chatterjee, Manash , Turner, David C. , Mayawala, Kapil , Elassaiss‐Schaap, Jeroen , Alwis, Dinesh P. de, Li, Xiaoyun , Ebbinghaus, Scot, Kang, Soonmo Peter, Kefford, Richard , Joseph, Richard W. , Puzanov, Igor , Robert, Caroline , Ribas, Antoni , Daud, Adil
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3068-3068